Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Jun 29;15(3):R160.
doi: 10.1186/cc10295.

High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery

Affiliations
Randomized Controlled Trial

High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery

Zaccaria Ricci et al. Crit Care. .

Abstract

Introduction: The aim of the study was to evaluate the effects of high-dose fenoldopam, a selective dopamine-1 receptor, on renal function and organ perfusion during cardiopulmonary bypass (CPB) in infants with congenital heart disease (CHD).

Methods: A prospective single-center randomized double-blind controlled trial was conducted in a pediatric cardiac surgery department. We randomized infants younger than 1 year with CHD and biventricular anatomy (with exclusion of isolated ventricular and atrial septal defect) to receive blindly a continuous infusion of fenoldopam at 1 μg/kg/min or placebo during CPB. Perioperative urinary and plasma levels of neutrophil gelatinase-associated lipocaline (NGAL), cystatin C (CysC), and creatinine were measured to assess renal injury after CPB.

Results: We enrolled 80 patients: 40 received fenoldopam (group F) during CPB, and 40 received placebo (group P). A significant increase of urinary NGAL and CysC levels from baseline to intensive care unit (ICU) admission followed by restoration of normal values after 12 hours was observed in both groups. However, urinary NGAL and CysC values were significantly reduced at the end of surgery and 12 hours after ICU admission (uNGAL only) in group F compared with group P (P = 0.025 and 0.039, respectively). Plasma NGAL and CysC tended to increase from baseline to ICU admission in both groups, but they were not significantly different between the two groups. No differences were observed on urinary and plasma creatinine levels and on urine output between the two groups. Acute kidney injury (AKI) incidence in the postoperative period, as indicated by pRIFLE classification (pediatric score indicating Risk, Injury, Failure, Loss of function, and End-stage kidney disease level of renal damage) was 50% in group F and 72% in group P (P = 0.08; odds ratio (OR), 0.38; 95% confidence interval (CI), 0.14 to 1.02). A significant reduction in diuretics (furosemide) and vasodilators (phentolamine) administration was observed in group F (P = 0.0085; OR, 0.22; 95% CI, 0.07 to 0.7).

Conclusions: The treatment with high-dose fenoldopam during CPB in pediatric patients undergoing cardiac surgery for CHD with biventricular anatomy significantly decreased urinary levels of NGAL and CysC and reduced the use of diuretics and vasodilators during CPB.

Trial registration: Clinical Trial.Gov NCT00982527.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of enrolment phases.
Figure 2
Figure 2
Urinary neutrophil gelatinase-associated lipocaline (uNGAL) levels. A significant increase of uNGAL levels from baseline (t0) to ICU admission (t1) and a consequent decrease after 12 hours (t2) was observed in both groups (P = 0.025). However, uNGAL values were significantly reduced in group F at t1 (P = 0.02) and t2 (P = 0.04) compared with group C (*).
Figure 3
Figure 3
Urinary cystatin-C (uCysC) levels. A significant increase of uCysC levels from baseline to ICU admission and a subsequent decrease after 12 hours was observed in both groups (P = 0.039). UCysC values were significantly reduced at t1 (P = 0.04) in group F with respect to group C (*).

Comment in

References

    1. Miller A, Lu CK, Wang S, Umstead TM, Freeman WM, Vrana K, Yang S, Myers JL, Phelps DS, Zahn JD, Undar A. Pediatric cardiopulmonary bypass circuits: a review of studies conducted at the Penn State Pediatric Cardiac Research Laboratories. J Extra Corpor Technol. 2009;41:P50–P58. - PMC - PubMed
    1. Murphy GS, Hessel EA, Groom RC. Optimal perfusion during cardiopulmonary bypass: an evidence-based approach. Anesth Analg. 2009;108:1394–1417. doi: 10.1213/ane.0b013e3181875e2e. - DOI - PubMed
    1. Chiravuri SD, Riegger LQ, Christensen R, Butler RR, Malviya S, Tait AR, Voepel-Lewis T. Factors associated with acute kidney injury or failure in children undergoing cardiopulmonary bypass: a case-controlled study. Paediatr Anaesth. 2011;21:880–886. doi: 10.1111/j.1460-9592.2011.03532.x. - DOI - PubMed
    1. Sirvinskas E, Andrejaitiene J, Raliene L, Nasvytis L, Karbonskiene A, Pilvinis V, Sakalauskas J. Cardiopulmonary bypass management and acute renal failure: risk factors and prognosis. Perfusion. 2008;23:323–327. doi: 10.1177/0267659109105251. - DOI - PubMed
    1. Zappitelli M, Bernier PL, Saczkowski RS, Tchervenkov CI, Gottesman R, Dancea A, Hyder A, Alkandari O. A small post-operative rise in serum creatinine predicts acute kidney injury in children undergoing cardiac surgery. Kidney Int. 2009;76:885–892. doi: 10.1038/ki.2009.270. - DOI - PubMed

Publication types

MeSH terms

Associated data